Monday, September 21, 2015

SCENESSE® Released for European Distribution

SCENESSE® Released for European Distribution


Clinuvel Pharmaceuticals Limited (ASX: CUV; ADR:CLVLY; XETRA:DAX) announces today that the European Medicines Agency’s (EMA’s) Pharmacovigilance and Risk Committee (PRAC) has agreed to a Post Authorisation Safety Study (PASS) protocol, allowing SCENESSE® (afamelanotide 16mg) to be released for the commercial supply to adult patients diagnosed with erythropoietic protoporphyria (EPP). While SCENESSE® was granted European marketing authorisation by the European Commission on 22 December 2014, it has taken a further nine months to gain agreement on the proposed PASS protocol.
Read the attachment from Clinuvel for the details: SCENESSE® released for European Distribution
                         "Remember....Research is the key to your cure!"


No comments:

Post a Comment

Happy Thanksgiving 2017

Happy Thanksgiving everyone 2017